-
Jun 5, 2024 | 
digitalcommons.library.tmc.edu | Mark Lebwohl |Leon Kircik |Angela Moore |Linda Gold
IMPORTANCE: Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in a phase 2b trial of patients with psoriasis. OBJECTIVE: To evaluate the efficacy of roflumilast cream, 0.3%, applied once daily for 8 weeks in 2 trials of patients with plaque psoriasis.
-
Jan 9, 2024 | 
dermatologytimes.com | Leon Kircik |George Han
January 9, 2024George Han, MD, discusses the latest biologic agents for plaque psoriasis, addressing the balance between efficacy and speed of response. Together with Dr. Leon Kircik, they emphasize the significance of comprehensive data for physician confidence and delve into the clinical utilization of these treatments, stressing the importance of baseline laboratory measurements for all prescribed patients.
-
Nov 13, 2023 | 
jofskin.org | Diamant Thaçi |Mark Lebwohl |Richard Warren |Leon Kircik
1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736. 2. Sotyktu [package insert]. Princeton, NJ, USA: Bristol Myers Squibb; September 2022. 3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023. 4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022. 5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022. 6. Sotyktu [product monograph].
-
Nov 13, 2023 | 
jofskin.org | Leon Kircik |Melinda Gooderham
Main Article Content Keywords Lebrikizumab, atopic dermatitis, itch, skin, improvement References 1. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547. 2.
-
Nov 13, 2023 | 
jofskin.org | Todd E. Schlesinger |April Armstrong |Vishal Patel |Leon Kircik
Introduction: Actinic Keratosis (AK) has been shown to negatively affect emotional and social functioning and skin-related quality of life [1].
-
Jul 16, 2023 | 
jofskin.org | Linda Gold |Leon Kircik |William Werschler |Hilary E. Baldwin
Main Article Content Keywords Pediatric, Adult, Acne, Male, Female, Retinoid, BPO, Adapalene, Clindamycin, Antibiotic, Combination Abstract Introduction: IDP-126 (clindamycin phosphate 1.2%/benzoyl peroxide [BPO] 3.1%/adapalene 0.15%) polymeric mesh gel is the first triple-combination, fixed-dose topical acne treatment in development. IDP-126 demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability, in a phase 2 and two phase 3 studies of participants with...
-
Jul 16, 2023 | 
jofskin.org | Zoe D. Draelos |Emil Tanghetti |Linda Gold |Leon Kircik
Main Article Content Keywords Tolerability, Irritation, CIPT, RIPT, Retinoid, BPO, Adapalene, Clindamycin, Antiobiotic, Combination Abstract Introduction: IDP-126 polymeric mesh gel (clindamycin phosphate 1.2%/benzoyl peroxide [BPO] 3.1%/adapalene 0.15%) is the first triple-combination, fixed-dose topical acne product in development and it addresses major acne pathophysiological processes. IDP-126 demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability in...
-
May 20, 2023 | 
jofskin.org | Todd E. Schlesinger |Leon Kircik |James Del Rosso |Darrell S. Rigel
Main Article Content Keywords actinic keratosis, topical treatment, tirbanibulin, patient-reported outcomes, clinician-reported outcomes Abstract Background: Patients' experiences regarding topical actinic keratosis (AK) treatments may optimize clinical outcomes. PROAK study aimed to evaluate patient- and clinician-reported outcomes among adult patients with AK on face or scalp who were prescribed tirbanibulin in real-world clinical practice in the United States. Methods: Key primary endpoint...
-
May 20, 2023 | 
jofskin.org | Steven Feldman |George Han |Valerie D. Callender |Leon Kircik
This work is licensed under a Creative Commons Attribution 4.0 International License. All authors retain copyright in their articles.
